Drug profile · INN
capmatinib hydrochloride hydrate
TABRECTA
capmatinib hydrochloride hydrate (TABRECTA) is a hepatocyte growth factor receptor inhibitor.
PMDA: approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — capmatinib hydrochloride hydrate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.78
Quick answer
capmatinib hydrochloride hydrate (TABRECTA) is a hepatocyte growth factor receptor inhibitor.
Key facts
INN capmatinib hydrochloride hydrate
Brand TABRECTA
Mechanism Hepatocyte growth factor receptor inhibitor
Target Hepatocyte growth factor receptor
Mechanism of action
Hepatocyte growth factor receptor inhibitor
Primary target: Hepatocyte growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is capmatinib hydrochloride hydrate?
capmatinib hydrochloride hydrate (TABRECTA) is a hepatocyte growth factor receptor inhibitor.
What is the brand name for capmatinib hydrochloride hydrate?
TABRECTA is a marketed brand name for capmatinib hydrochloride hydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.